WB with anti-AAV VP1/VP2/VP3 antibody (Cat. No. 61058, 1:250) using AAV2 capsids as sample

anti-AAV VP1/VP2/VP3 mouse monoclonal, B1, lyophilized, purified

Useful for immunolocalization studies of capsid formation in combination with Cat. No. 61055 and rabbit anti-AAV (Cat. No. 61084). Reacts with free VP1, VP2 and VP3 and at a very reduced level with assembled capsids. Recognizes all published AAV serotypes (AAV4, 11 & 12, no cross-reaction)

Cat. No.: 61058
Quantity: 50 µg

Delivery Time: usually 1-7 working days

$450.00

Excl. VAT, excl. Shipping Cost

Qty:

Publication

Species

Application

Blessing, D. et al. Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells. Mol.Ther.Methods.Clin.Dev. 13, 14-26 (2019)

human

Wu, Y. et al. Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production. Hum.Gene.Ther.Methods. 30, 172-183 (2019)

AAV2

Feiner, R. et al. rAAV Engineering for Capsid-Protein Enzyme Insertions and Mosaicism Reveals Resilience to Mutational, Structural and Thermal Perturbations. Int.J.Mol.Sci. 20, (2019)

AAV2

Wu, Y. et al. A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. Mol.Ther.Methods.Clin.Dev. 10, 38-47 (2018).

AAV2

Schiller, L. et al. Enhanced Production of Exosome-Associated AAV by Overexpression of the Tetraspanin CD9. Mol.Ther.Methods.Clin.Dev. 9, 278-287 (2018).

AAV2

Galibert, L. et al. Origins of truncated supplementary capsid proteins in rAAV8 vectors produced with the baculovirus system. PLoS.One. 13, e0207414 (2018).

AAV8

Maddalena, A. et al. High-Throughput Screening Identifies Kinase Inhibitors That Increase Dual Adeno-Associated Viral Vector Transduction In Vitro and in Mouse Retina. Hum.Gene.Ther. 29, 886-901 (2018).

AAV2

Tomono, T. et al. Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9. Mol.Ther.Methods.Clin.Dev. 11, 180-190 (2018)

AAV9

Meliani, A. et al. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood.Adv. 1, 2019-2031 (2017).

AAV8

Tseng, Y.-S. et al. Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. J. Virol. Methods 236, 105â110 (2016).

AAV1
AAV2
AAV3
AAV5
AAV6
AAV7
AAV8
AAV9

dot blot

Mietzsch, M. et al. OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1â12 Vectors for Gene Therapy. Hum. Gene Ther. 25, 212â222 (2014).

AAV1
AAV2
AAV3
AAV5
AAV6
AAV7
AAV8
AAV9
AAVrh10

Jin, L.-F. et al. Ultrasound Targeted Microbubble Destruction Stimulates Cellular Endocytosis in Facilitation of Adeno-Associated Virus Delivery. Int. J. Mol. Sci 14, 9737â9750 (2013).

AAV5

Naumer, M. et al. Properties of the Adeno-Associated Virus Assembly-Activating Protein. J. Virol. 86, 13038â13048 (2012).

AAV2

WB
dot blot

Sonntag, F. et al. The Assembly-Activating Protein Promotes Capsid Assembly of Different Adeno-Associated Virus Serotypes. J. Virol. 85, 12686â12697 (2011).

AAV1
AAV2
AAV5
AAV8
AAV9

Fragkos, M., Breuleux, M., ClÃ©ment, N. & Beard, P. Recombinant Adeno-Associated Viral Vectors Are Deficient in Provoking a DNA Damage Response. J. Virol. 82, 7379â7387 (2008).

AAV2

Kuck, D., Kern, A. & Kleinschmidt, J. A. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140, 17â24 (2007).

AAV1
AAV5
AAV6

WB
ICC-IF

Grimm, D., Kay, M. A. & Kleinschmidt, J. A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839â850 (2003).

AAV2

Yan, Z. et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors. J. Virol. 76, 2043â2053 (2002).

AAV2
AAV5

Zhang, H.-G. et al. Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production. J. Virol. 76, 12023â12031 (2002).

AAV2

Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281â93 (2000)

AAV2

epitope mapping

Wistuba, A. et al. Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly. J. Virol. 71, 1341â1352 (1997).

AAV2

WB
IP
ICC-IF

Wistuba, A., Weger, S., Kern, A., Rgen, J. & Kleinschmidt, A. Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins. J. Virol. 69, 5311â5319 (1995).

AAV2

Alternative Products

Cat. No.	Product Name	Format	Quantity	Price
65158	anti-AAV VP1/VP2/VP3 mouse monoclonal, B1	supernatant	5 mL	$265.00 Excl. VAT, excl. Shipping Cost
61058S	anti-AAV VP1/VP2/VP3 mouse monoclonal, B1	lyophilized, purified, sample	10 µg	$128.00 Excl. VAT, excl. Shipping Cost
61058-488	Anti-AAV VP1/VP2/VP3 mouse monoclonal, B1	AFDyeTM 488 Conjugate	50 µg (100 µl)	$498.00 Excl. VAT, excl. Shipping Cost
61058-647	Anti-AAV VP1/VP2/VP3 mouse monoclonal, B1	AFDyeTM 647 Conjugate	50 µg (100 µl)	$498.00 Excl. VAT, excl. Shipping Cost

Product description

Host	mouse
Antibody Type	monoclonal
Isotype	IgG1
Clone	B1
Immunogen	AAV2 capsids
Purification	protein A affinity chromatography
Conjugate	unconjugated
Formulation	lyophilized; reconstitute in 1 ml sterile PBS
Storage	lyophilized antibody: 2-8°C; reconstituted antibody: short term at 2-8°C; for long term storage we recommend to add 0.5% BSA prior to storing in aliquots at -20°C; avoid freeze/thaw cycles
Intended use	Research use only
Tested species reactivity	AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh10, AAVDJ

Applications

Tested applications	Tested dilutions
Affinity Chromatography	assay dependent
Dot Blot	1:500 (0.1 µg/ml; denaturing conditions)
Immunocytochemistry (ICC)/ Immunofluorescence (IF)	assay dependent
Immunoprecipitation (IP)	assay dependent (precipitation of mainly free VP proteins)
Western Blot (WB)	1:250 - 1:500 (0.1 - 0.2 µg/ml)

Background

Details

B1 reacts with free VP1, VP2 and VP3 of adeno-associated virus (AAV) and at a very reduced degree with assembled capsids. VP1 and VP2 are highly enriched in the nucleus, while non-assembled VP3 is evenly distributed in the nucleus and the cytoplasm. Epitope mapping experiments (Wobus et al. 2000) identified aa726 to aa733 (C-terminus; common to all 3 VP proteins) as the specific binding region. The antibody is also useful for characterization of different stages of infection.

Limited Use Label License: Research Use Only
Product is exclusively licensed to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.

Reference

Publication

Species

Application

Blessing, D. et al. Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells. Mol.Ther.Methods.Clin.Dev. 13, 14-26 (2019)

human

AAV2

Feiner, R. et al. rAAV Engineering for Capsid-Protein Enzyme Insertions and Mosaicism Reveals Resilience to Mutational, Structural and Thermal Perturbations. Int.J.Mol.Sci. 20, (2019)

AAV2

Wu, Y. et al. A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. Mol.Ther.Methods.Clin.Dev. 10, 38-47 (2018).

AAV2

Schiller, L. et al. Enhanced Production of Exosome-Associated AAV by Overexpression of the Tetraspanin CD9. Mol.Ther.Methods.Clin.Dev. 9, 278-287 (2018).

AAV2

Galibert, L. et al. Origins of truncated supplementary capsid proteins in rAAV8 vectors produced with the baculovirus system. PLoS.One. 13, e0207414 (2018).

AAV8

AAV2

Tomono, T. et al. Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9. Mol.Ther.Methods.Clin.Dev. 11, 180-190 (2018)

AAV9

Meliani, A. et al. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood.Adv. 1, 2019-2031 (2017).

AAV8

Tseng, Y.-S. et al. Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. J. Virol. Methods 236, 105â110 (2016).

AAV1
AAV2
AAV3
AAV5
AAV6
AAV7
AAV8
AAV9

dot blot

Mietzsch, M. et al. OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1â12 Vectors for Gene Therapy. Hum. Gene Ther. 25, 212â222 (2014).

AAV1
AAV2
AAV3
AAV5
AAV6
AAV7
AAV8
AAV9
AAVrh10

Jin, L.-F. et al. Ultrasound Targeted Microbubble Destruction Stimulates Cellular Endocytosis in Facilitation of Adeno-Associated Virus Delivery. Int. J. Mol. Sci 14, 9737â9750 (2013).

AAV5

Naumer, M. et al. Properties of the Adeno-Associated Virus Assembly-Activating Protein. J. Virol. 86, 13038â13048 (2012).

AAV2

WB
dot blot

Sonntag, F. et al. The Assembly-Activating Protein Promotes Capsid Assembly of Different Adeno-Associated Virus Serotypes. J. Virol. 85, 12686â12697 (2011).

AAV1
AAV2
AAV5
AAV8
AAV9

Fragkos, M., Breuleux, M., ClÃ©ment, N. & Beard, P. Recombinant Adeno-Associated Viral Vectors Are Deficient in Provoking a DNA Damage Response. J. Virol. 82, 7379â7387 (2008).

AAV2

Kuck, D., Kern, A. & Kleinschmidt, J. A. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140, 17â24 (2007).

AAV1
AAV5
AAV6

WB
ICC-IF

AAV2

Yan, Z. et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors. J. Virol. 76, 2043â2053 (2002).

AAV2
AAV5

Zhang, H.-G. et al. Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production. J. Virol. 76, 12023â12031 (2002).

AAV2

epitope mapping

Wistuba, A. et al. Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly. J. Virol. 71, 1341â1352 (1997).

AAV2

WB
IP
ICC-IF

AAV2

Material safety data sheet

Please complete the form below to request a material safety data sheet

Personal Info

* Company / Institution

Name
* Country

Phone
* E-mail address
* Privacy declaration
- By submitting the above request you agree that PROGEN stores and uses the data provided by you in accordance with the terms of use provided in the privacy declaration in order to process your request. You also agree that PROGEN may contact you with regard to your request or for marketing purposes (e.g. Mailchimp-Emailings). You can revoke your permission at any time without giving any reasons by sending an Email to info@progen.com or by writing to PROGEN at Maaßstraße 30, 69123 Heidelberg/Germany.

* Required Fields

Product Request

Personal Info

* Company / Institution

Name
* Country

Phone
* E-mail address
* Ask your question
* Privacy declaration
- By submitting the above request you agree that PROGEN stores and uses the data provided by you in accordance with the terms of use provided in the privacy declaration in order to process your request. You also agree that PROGEN may contact you with regard to your request or for marketing purposes (e.g. Mailchimp-Emailings). You can revoke your permission at any time without giving any reasons by sending an Email to info@progen.com or by writing to PROGEN at Maaßstraße 30, 69123 Heidelberg/Germany.

* Required Fields

anti-AAV VP1/VP2/VP3 mouse monoclonal, B1, lyophilized, purified

Alternative Products